Loading...
Emerging serine-threonine kinase inhibitors for treating ovarian cancer
INTRODUCTION: Ovarian cancer is the leading cause of gynecologic cancer death, owing to high rates of incurable, recurrent disease after initial treatment. Serine threonine kinases (STKs) have been proposed as potential therapeutic targets in ovarian cancer because of their role in the initiation an...
Na minha lista:
| Udgivet i: | Expert Opin Emerg Drugs |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7526049/ https://ncbi.nlm.nih.gov/pubmed/31755325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14728214.2019.1696773 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|